MDR-ABC transporters: biomarkers in rheumatoid arthritis

CER6166
2013 Vol.31, N°5
PI 0779, PF 0787
Review

Free to view
(click on article PDF icon to read the article)

PMID: 23711386 [PubMed]

Received: 28/11/2012
Accepted : 05/02/2013
In Press: 27/05/2013
Published: 19/09/2013

Abstract

MDR-ABC transporters are widely expressed in cell types relevant to pathogenesis of rheumatoid arthritis. Many reports demonstrate the interaction of small molecule drugs with MDR-ABC transporters. Cell-based assays for disease relevant cell types can be easily gated and could reveal specific drug targets and may increase significance and utilisation of data in clinical practice. Many commonly used DMARDs (e.g. methotrexate, sulfasalazine, leflunomide/teriflunomide, hydroxychloroquine) are ABCG2 substrates. Consequently, the activity of this transporter in patients should be determined to understand the disposition and pharmacokinetics of the therapy. In addition, MDR-ABC transporters transport a variety of endobiotics that play important roles in cell proliferation, cell migration, angiogenesis and inflammation. Therefore, MDR-ABC transporters are important biomarkers in rheumatoid arthritis.